121216-43-1

Basic information

• Product Name: (R)-(+)-7-METHOXY 2-AMINOTETRALIN
• Synonyms: (R)-7-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YLAMINE;(R)-(+)-7-METHOXY 2-AMINOTETRALIN;(R)-7-METHOXY-2-AMINOTETRALIN;(R)-2-Amino-7-methoxy-1,2,3,4-tetrahydronaphthalene;7-Methoxy-2-aminotetralin;(R)-2-Amino-7-methoxytetralin;=-2-aMine-7-Methoxytetralin;(R)-2-(N-benaylaMine)-7-Methoxytetralin
• CAS NO: 121216-43-1
• Molecular Formula: C11H15NO
• Molecular Weight: 177.24
• Mol File: 121216-43-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 299.6 °C at 760 mmHg
• Flash Point: 139.7 °C
• Appearance: /
• Density: 1.056 g/cm³
• Vapor Pressure: 0.00118mmHg at 25°C
• Refractive Index: 1.547
• CAS DataBase Reference: (R)-(+)-7-METHOXY 2-AMINOTETRALIN(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(+)-7-METHOXY 2-AMINOTETRALIN(121216-43-1)
• EPA Substance Registry System: (R)-(+)-7-METHOXY 2-AMINOTETRALIN(121216-43-1)

Safety Data

• Hazardous Substances Data: 121216-43-1(Hazardous Substances Data)

Usage

General Description

(R)-(+)-7-Methoxy 2-Aminotetralin is a chemical compound that belongs to the class of tetralin derivatives. It is a racemic mixture, meaning it exists as two enantiomers, with the (R)-(+)-enantiomer being the active form. (R)-(+)-7-METHOXY 2-AMINOTETRALIN is commonly used in scientific research as a ligand for studying serotonin receptors in the brain. It has also been investigated for its potential use in the treatment of neurological disorders and mood-related conditions. The (R)-(+)-7-Methoxy 2-Aminotetralin has shown promising pharmacological activity in preclinical studies and is being researched for its therapeutic potential.

InChI:InChI=1/C11H15NO/c1-13-11-5-3-8-2-4-10(12)6-9(8)7-11/h3,5,7,10H,2,4,6,12H2,1H3/t10-/m1/s1

Upstream product

• 83343-23-1 N-benzyl-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 
• 3880-78-2 7-Methoxy-1,2,3,4-tetrahydro-(2R)-2-naphthaleneamine hydrochloride 
• 4133-34-0 7-methoxyl-2-tetralone 
• 121251-89-6 (R)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine (S)-mandelate 
• 4003-89-8 2-amino-7-methoxy-1,2,3,4-tetrahydronaphthalene 

Downstream Products

• 1274816-90-8 N-[(2R)-7-((2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide 
• 220640-10-8 (7R)-7-amino-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide 
• 121524-07-0 N-<(2R)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl>-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine 
• 121489-28-9 [(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethyl]-((R)-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid tert-butyl ester 
• 121251-87-4 (+)-N-<(2R)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(S)-3-chloromandelamide 
• 121251-83-0 (+)-N-<(2R)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(R)-3-chloromandelamide 
• 121216-36-2 (+)-N-<(2R)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(S)-mandelamide 
• 121216-35-1 (+)-N-<(2R)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(R)-mandelamide 
• 121216-30-6 N-<(2'R)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(2S)-2-(3-chlorphenyl)-2-hydroxyethanamine 
• 121489-40-5 N-<(2R)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(2R)-2-(3-chlorphenyl)-2-hydroxyethanamine 
• 85951-61-7 (+)-7-OH-AT 

Relevant articles and documents

Asymmetric amination of tetralone and chromanone derivatives employing ω-transaminases

Various (S)-selective and (R)-selective ω-transaminases were investigated for the amination of 1- and 2-tetralone and derivatives as well as of 3- and 4-chromanone. All ketones tested were aminated to give the corresponding enantiopure amines (ee > 99%) employing at least one of the enzymes investigated. In most of the cases the (S)- as well as the (R)-enantiomer was obtained in optically pure form. The amination of 3-chromanone was performed on a 100 mg scale leading to optically pure (R)-3-aminochromane (ee > 99%) with complete conversion and 78% isolated yield.

Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors

Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

PREPARATION OF AMINOTETRALIN COMPOUNDS

The present invention relates to synthetic processes for preparation of aminotetralin compounds with kinase inhibitory activity. The invention also provides synthetic intermediates useful in the processes of the invention.